keyword
MENU ▼
Read by QxMD icon Read
search

Schizophrenia sleep

keyword
https://www.readbyqxmd.com/read/28078741/effect-of-an-art-brut-therapy-program-called-go-beyond-the-schizophrenia-gbts-on-prison-inmates-with-schizophrenia-in-mainland-china-a-randomized-longitudinal-and-controlled-trial
#1
Hong-Zhong Qiu, Zeng-Jie Ye, Mu-Zi Liang, Yue-Qun Huang, Wei Liu, Zhi-Dong Lu
: Creative arts therapies are proven to promote an interconnection between body and mind, but there are major obstacles for providing therapeutic services in prisons due to inmates' inherent mistrust for verbal disclosure and rigid self-defenses, especially among inmates with schizophrenia. Thus, we developed a structured and quantitative art brut therapy program called go beyond the schizophrenia to actually measure the benefits of art therapy on prison inmates in mainland China. Upon completion of the program, the intervention group reported a decrease in anxiety, depression, anger, and negative psychiatric symptoms and showed better compliance with rules, socialization with peers, compliance with medications, and regular sleeping patterns after 16 weekly sessions of go beyond the schizophrenia...
January 12, 2017: Clinical Psychology & Psychotherapy
https://www.readbyqxmd.com/read/28049075/abnormal-brain-oscillations-persist-after-recovery-from-bipolar-depression
#2
P Canali, S Casarotto, M Rosanova, G Sferrazza-Papa, A G Casali, O Gosseries, M Massimini, E Smeraldi, C Colombo, F Benedetti
When directly perturbed in healthy subjects, premotor cortical areas generate electrical oscillations in the beta range (20-40Hz). In schizophrenia, major depressive disorder and bipolar disorder (BD), these oscillations are markedly reduced, in terms of amplitude and frequency. However, it still remains unclear whether these abnormalities can be modulated over time, or if they can be still observed after treatment. Here, we employed transcranial magnetic stimulation (TMS) combined with EEG to assess the frontal oscillatory activity in eighteen BD patients before/after antidepressant treatments (sleep deprivation and light therapy), relative to nine healthy controls...
December 27, 2016: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/27992416/genome-wide-association-analyses-of-sleep-disturbance-traits-identify-new-loci-and-highlight-shared-genetics-with-neuropsychiatric-and-metabolic-traits
#3
Jacqueline M Lane, Jingjing Liang, Irma Vlasac, Simon G Anderson, David A Bechtold, Jack Bowden, Richard Emsley, Shubhroz Gill, Max A Little, Annemarie I Luik, Andrew Loudon, Frank A J L Scheer, Shaun M Purcell, Simon D Kyle, Deborah A Lawlor, Xiaofeng Zhu, Susan Redline, David W Ray, Martin K Rutter, Richa Saxena
Chronic sleep disturbances, associated with cardiometabolic diseases, psychiatric disorders and all-cause mortality, affect 25-30% of adults worldwide. Although environmental factors contribute substantially to self-reported habitual sleep duration and disruption, these traits are heritable and identification of the genes involved should improve understanding of sleep, mechanisms linking sleep to disease and development of new therapies. We report single- and multiple-trait genome-wide association analyses of self-reported sleep duration, insomnia symptoms and excessive daytime sleepiness in the UK Biobank (n = 112,586)...
December 19, 2016: Nature Genetics
https://www.readbyqxmd.com/read/27960654/a-case-of-dose-escalation-of-quetiapine-in-persistent-insomnia-disorder
#4
Claudia Cornelis, Ann Van Gastel, Glenn Dumont, Violette Coppens, Bernard Sabbe, Manuel Morrens, Filip Van Den Eede
Quetiapine, an atypical antipsychotic drug, is recommended for the treatment of schizophrenia and mood disorders. In addition, given its sedative effects, a low dose of the agent is also widely used in the treatment of anxiety disorders, personality disorders, substance abuse, and sleep disturbances. In this case study, quetiapine was the first effective drug in reducing chronic insomnia in a male patient with a long treatment history. Because its effect declined over time, in the course of two years, a gradual dose increase led to a posology 50 times higher than the off-label dosage used to obtain sedation, i...
December 14, 2016: Acta Clinica Belgica
https://www.readbyqxmd.com/read/27931914/schizophrenia-and-depression-the-relation-between-sleep-quality-and-working-memory
#5
Maurits van den Noort, Esli Struys, Benoît Perriard, Heike Staudte, Sujung Yeo, Sabina Lim, Peggy Bosch
Sleep is known to be markedly disturbed in patients with depression, but in patients with schizophrenia these problems are underestimated. This research aimed to determine if a relationship existed between sleep problems in patients with schizophrenia and with depression and their reduced working memory (WM) performance. Thirty outpatients with schizophrenia, 30 outpatients with depression, and 30 healthy control participants were enrolled in this study. All participants completed a sleep questionnaire (i.e...
December 2016: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/27891431/excessive-daytime-sleepiness-in-schizophrenia-a-naturalistic-clinical-study
#6
Payal Sharma, Reetika Dikshit, Nilesh Shah, Sagar Karia, Avinash De Sousa
INTRODUCTION: Excessive Daytime Sleepiness (EDS) and sleep problems are common in patients with schizophrenia. The symptom of EDS in schizophrenia can be attributed to various causes including neurobiological changes, sleep disorders, medication or as a symptom of schizophrenia itself. EDS as a symptom in schizophrenia has been understudied. AIM: To assess the prevalence of EDS and to the study the same in patients with first episode and chronic schizophrenia. MATERIALS AND METHODS: In this cross-sectional study 100 patients suffering from schizophrenia as per International Classification of Diseases (ICD-10) criteria were evaluated for sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and EDS using the Epworth Sleepiness Scale (ESS)...
October 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27863313/an-examination-of-sleep-quality-in-veterans-with-a-dual-diagnosis-of-ptsd-and-severe-mental-illness
#7
Wilson J Brown, Allison K Wilkerson, Melissa E Milanak, Peter W Tuerk, Thomas W Uhde, Bernadette M Cortese, Anouk L Grubaugh
Poor sleep quality is one of the most frequently reported symptoms by veterans with Posttraumatic Stress Disorder (PTSD) and by veterans with severe mental illness (SMI; i.e., schizophrenia spectrum disorders, bipolar disorder, major depression with or without psychotic features). However, little is known about the compounding effects of co-occurring PTSD/SMI on sleep quality in this population. Given the high rates of comorbidity and poor functional outcomes associated with sleep dysfunction, there is a need to better understand patterns of poor sleep quality in this population...
January 2017: Psychiatry Research
https://www.readbyqxmd.com/read/27861956/the-prevalence-of-sleep-disturbance-and-its-socio-demographic-and-clinical-correlates-in-first-episode-individuals-with-schizophrenia-in-rural-china
#8
Xin-Rong Ma, Guang-Rong Song, Xue-Bing Xu, Tao Tian, Shao-Hua Chang
PURPOSE: This study aimed to determine the prevalence and the socio-demographic and clinical correlates of sleep disturbance in first-episode individuals with schizophrenia in rural China and the factors that impact sleep among individuals with schizophrenia. DESIGN AND METHODS: A total of 104 first-episode individuals with schizophrenia were randomly selected in rural areas in Ningxia, China, in 2015 as the study sample. FINDINGS: In first-episode individuals with schizophrenia, the prevalence of sleep disturbance was 78...
November 8, 2016: Perspectives in Psychiatric Care
https://www.readbyqxmd.com/read/27846049/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#9
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
October 29, 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27824682/treating-schizophrenia-during-menopause
#10
Amnon Brzezinski, Noa A Brzezinski-Sinai, Mary V Seeman
OBJECTIVE: The aim of this review is to examine three questions: What are the risks and benefits of treating women with schizophrenia with hormone therapy (HT) at menopause? Should the antipsychotic regimen be changed at menopause? Do early- and late-onset women with schizophrenia respond differently to HT at menopause? METHODS: MEDLINE databases for the years 1990 to 2016 were searched using the following interactive terms: schizophrenia, gender, menopause, estrogen, and hormones...
November 7, 2016: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/27815720/the-role-of-endoplasmic-reticulum-stress-in-neurodegenerative-disease
#11
REVIEW
Chunchen Xiang, Yujia Wang, Han Zhang, Fang Han
The endoplasmic reticulum (ER) is an important organelle involved in cellular homeostasis and control of protein quality. Unfolded protein response (UPR) is a cellular response to ER stress and promotes cell survival. Severe or prolonged stress activates apoptosis signaling to trigger cell death. In mammals, the UPR is initiated by three major ER stress sensors, including inositol-requiring transmembrane kinase 1, double-stranded RNA-activated protein kinase-like ER kinase and activating transcription factor 6...
November 4, 2016: Apoptosis: An International Journal on Programmed Cell Death
https://www.readbyqxmd.com/read/27805978/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#12
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
December 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27804883/pros-and-cons-of-medical-cannabis-use-by-people-with-chronic-brain-disorders
#13
Uma Suryadevara, Dawn M Bruijnzeel, Meena Nuthi, Darin A Jagnarine, Rajiv Tandon, Adriaan W Bruijnzeel
BACKGROUND: Cannabis is the most widely used illicit drug in the world and there is growing concern about the mental health effects of cannabis use. These concerns are at least partly due to the strong increase in recreational and medical cannabis use and the rise in tetrahydrocannabinol (THC) levels. Cannabis is widely used to self-medicate by older people and people with brain disorders such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), bipolar disorder, and schizophrenia...
October 31, 2016: Current Neuropharmacology
https://www.readbyqxmd.com/read/27755061/lassbio-1422-a-new-molecular-scaffold-with-efficacy-in-animal-models-of-schizophrenia-and-disorders-of-attention-and-cognition
#14
Andresa H Betti, Camila B Antonio, Thais E T Pompeu, Thaise S Martins, Vivian Herzfeldt, Eveline D Stolz, Carlos A M Fraga, Eliezer Barreiro, François Noël, Stela M K Rates
Aiming to identify new antipsychotic lead-compounds, our group has been working on the design and synthesis of new N-phenylpiperazine derivatives. Here, we characterized LASSBio-1422 as a pharmacological prototype of this chemical series. Adult male Wistar rats and CF1 mice were used for in-vitro and in-vivo assays, respectively. LASSBio-1422 [1 and 5 mg/kg, postoperatively (p.o.)] inhibited apomorphine-induced climbing as well as ketamine-induced hyperlocomotion (1 and 5 mg/kg, p.o.), animal models predictive of efficacy on positive symptoms...
October 13, 2016: Behavioural Pharmacology
https://www.readbyqxmd.com/read/27697656/associations-between-sleep-quality-and-inflammatory-markers-in-patients-with-schizophrenia
#15
Shih-Hua Fang, Katsuhiko Suzuki, Chin Leong Lim, Ming-Shun Chung, Po-Wen Ku, Li-Jung Chen
Sleep disorder is a risk factor for several systemic inflammation-related diseases and there are extensive data showing that schizophrenia is associated with chronic low-grade systemic inflammation. This study investigated the associations between sleep quality and inflammatory markers in patients with schizophrenia, which has not been examined before. Sleep quality (total sleep time, sleep efficiency, sleep onset latency, total activity counts, wake after sleep onset, number of awakening, and average length of awakening) was measured using actigraphy in 199 schizophrenia inpatients...
December 30, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/27663065/what-are-sleep-spindle-deficits-telling-us-about-schizophrenia
#16
Fabio Ferrarelli, Giulio Tononi
No abstract text is available yet for this article.
October 15, 2016: Biological Psychiatry
https://www.readbyqxmd.com/read/27634797/coordination-of-slow-waves-with-sleep-spindles-predicts-sleep-dependent-memory-consolidation-in-schizophrenia
#17
Charmaine Demanuele, Ullrich Bartsch, Bengi Baran, Sheraz Khan, Mark G Vangel, Roy Cox, Matti Hämäläinen, Matthew W Jones, Robert Stickgold, Dara S Manoach
STUDY OBJECTIVES: Schizophrenia patients have correlated deficits in sleep spindle density and sleep-dependent memory consolidation. In addition to spindle density, memory consolidation is thought to rely on the precise temporal coordination of spindles with slow waves (SWs). We investigated whether this coordination is intact in schizophrenia and its relation to motor procedural memory consolidation. METHODS: Twenty-one chronic medicated schizophrenia patients and 17 demographically-matched healthy controls underwent two nights of polysomnography with training on the finger tapping motor sequence task (MST) on the second night and testing the following morning...
September 9, 2016: Sleep
https://www.readbyqxmd.com/read/27629985/the-relationship-between-sleep-patterns-quality-of-life-and-social-and-clinical-characteristics-in-chinese-patients-with-schizophrenia
#18
Cai-Lan Hou, Yu Zang, Xin-Rong Ma, Mei-Ying Cai, Yan Li, Fu-Jun Jia, Yong-Qiang Lin, Helen F K Chiu, Gabor S Ungvari, Chee H Ng, Bao-Liang Zhong, Xiao-Lan Cao, Man-Ian Tam, Yu-Tao Xiang
PURPOSE: The purpose of the study was to determine the pattern of sleep behavior in schizophrenia patients treated in primary care. DESIGN AND METHODS: Altogether 623 schizophrenia patients in 22 primary care services were recruited. Sleep duration and demographic and clinical characteristics were recorded. FINDINGS: The mean expected total sleep time was 8.8 hr (SD 1.8) and the mean actual total sleep time was 8.2 hr (SD 2.1). The frequency of short, medium, and long sleepers was 18...
September 14, 2016: Perspectives in Psychiatric Care
https://www.readbyqxmd.com/read/27609312/pimavanserin-for-the-treatment-of-parkinson-s-disease-psychosis
#19
Ines Chendo, Joaquim J Ferreira
INTRODUCTION: Parkinson´s disease (PD) is a synucleinopathy that affects millions of people worldwide and leads to progressive disability. Psychosis is highly prevalent in PD patients and is associated with poor prognosis. Until April 2016, there were no licensed drugs available in the United States of America (USA) for the treatment of PD psychosis (PDP). Pimavanserin is the first Food and Drug Administration approved medicine for the treatment of hallucinations and delusions associated with PDP...
October 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27597833/health-behaviors-knowledge-life-satisfaction-and-wellbeing-in-people-with-mental-illness-across-four-countries-and-comparisons-with-normative-sample
#20
Natalie Parletta, Yousef Aljeesh, Bernhard T Baune
BACKGROUND: People with chronic mental illness have poorer physical health and higher mortality than the general population. We investigated lifestyle factors in people with mental illness across four countries and compared with a normative sample. DESIGN AND METHODS: Data were collected from N = 672 people (Germany, n = 375; Palestine, n = 192; London, n = 63; Australia, n = 42) with substance abuse disorder (n = 224), schizophrenia (n = 158), mood disorders (n = 227), and somatoform disorders (n = 63)...
2016: Frontiers in Psychiatry
keyword
keyword
3094
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"